Sarbanes-Oxley Section 404: New Evidence on the Cost for Small Companies (December 12, 2007)
The Statement from BIO to the House Committee on Small Business
Read the statement (247 KB PDF)
Read the press release

Sarbanes-Oxley Section 404 (June 5, 2007)
Testimony by Jim Greenwood, President and CEO, BIO before a hearing held by the House Committee on Small Business entitled "Will the SEC's and PCAOB's New Standards Lower Compliance Costs for Small Companies?"
Read the testimony (640 KB PDF)

Biotech Research and Development Will Benefit from Sarbanes-Oxley Changes (April 18, 2007)
BIO Reiterates Support as Senate Small Business Committee Considers Changes
Read the press release

The COMPETE Act of 2007 (March 14, 2007)
BIO Letters to Congressman Meeks and Feeney and Senator DeMint on their introduction of the Competitive and Open Markets that Protect and Enhance the Treatment of Entrepreneurs Act.
Letter to Congressman Meeks (592 KB PDF)
Letter to Congressman Feeney (508 KB PDF)
Letter to Senator DeMint (912 KB PDF)

Comments on Sarbanes-Oxley (February 26, 2007)
BIO Applauds both the SEC and PCAOB for acknowledging that implementation of Section 404 should be scaled to the size of the company and proportionate to the complexity of underlying corporate structures.
Read the comments (587 KB PDF)

BIO Issues Statement On Anticipated Changes to Sarbanes-Oxley Implementation (December 13, 2006)
"I commend SEC Chairman Chris Cox and the Commissioners for recognizing that the present implementation of Sarbanes Oxley is not working. Relaxing these burdensome regulations is a welcome development that is long overdue."
Read Jim Greenwood's statement

BIO, High-Growth Industries Urge SEC to Adopt Section 404 reforms
BIO and other high-growth industries submit comments to the Securities and Exchange Commission (SEC) urging officials to expeditiously adopt Section 404 reforms based on a framework that is cost-effective, "scaled" and "proportional" to the size and complexity of corporate structures.
Read the letter (452 KB PDF)

Biotech CFO Testifies at House Field Hearing on Sarbanes-Oxley Reform
David Lawrence, chief financial officer of Acorda Therapeutics Inc., will testified on behalf of BIO at the House Government Reform Subcommittee on Regulatory Affairs field hearing regarding reform to Section 404 of the Sarbanes-Oxley Act of 2002.
Read the testimony (59 KB PDF)

EntreMed CEO Testifies Before House Committee on Sarbanes-Oxley Reform
James S. Burns, president and CEO of Rockville, Md.-based EntreMed Inc., testified on behalf of BIO regarding the unintended consequences of Sarbanes-Oxley, the corporate governance law. (May 3, 2006)
Read the testimony (64 KB PDF)

Cell Genesys Chairman and CEO Comments to the SEC and Public Accounting Oversight Board
Stephen A. Sherwin, Chairman and CEO of Cell Genesys, Inc. commented on behalf of BIO regarding the issues faced by small companies faced with Section 404 compliance. (May 1, 2006)
Read the comments (58 KB PDF)

Final Report of the Advisory Committee on Smaller Public Companies
Report to the SEC on general regulatory issues, specifically considering the impact of the Sarbanes-Oxley Act. (April 18, 2006)
Read the letter
Read the press release

Multi-industry coalition letter to SEC
Letter to the SEC from ten industry leaders. (April 3, 2006)
Read the letter
Read the press release

SEC Advisory Committee Favorable to Sarbanes-Oxley Reforms
The SEC's Advisory Committee on Smaller Public Companies voted overwhelmingly in favor of reforming Section 404 of the Sarbanes-Oxley Act of 2002. (December 14, 2005)
Read the press release

Coalition of Biotech, High-Tech Industries Seek Sarbanes-Oxley Regulatory Reform
Submit letter to an SEC advisory committee (December 8, 2005)
Read the Letter (52 KB PDF)
Read the Press Release

Letter to SEC
on smaller public companies. (October 17, 2005)
Read the letter (47 KB PDF)